All In Biotech

Investigational drug · Phase 3

SHR-A1811

Also called: Trastuzumab Rezetecan

Not approved by FDA. In 27 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

27

27 still active

All registered trials

109

Any phase or sponsor naming "SHR-A1811"

First trial start

2022

Aug 4, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SHR-A1811", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Colorectal Cancer
  • Recurrent or Metastatic Cervical Cancer
  • Ovarian Cancer
  • PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
  • Early-stage or Locally Advanced HER2-positive Breast Cancer
  • Breast Cancer
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • HER2-expressing Advanced Solid Tumors
  • Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma

Approved drugs for the same conditions: Breast cancer · Colorectal cancer · Ovarian cancer · Stomach and esophageal cancer · Cervical cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "SHR-A1811" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 34 on PubMed

Also in development for Advanced Colorectal Cancer

  • JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials

    Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor

  • B1962Phase 22 trials

    Tasly Biopharmaceuticals Co., Ltd. · Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers

  • RBS2418Phase 22 trials

    Riboscience, LLC. · Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Unresectable Hepatocellular Carcinoma

  • VEGF antibodyPhase 22 trials

    Lepu Biopharma Co., Ltd. · Hepatocellular Carcinoma, Advanced Colorectal Cancer

  • MRG007Phase 21 trial

    Lepu Biopharma Co., Ltd. · Advanced Colorectal Cancer

  • TL938Phase 21 trial

    Teligene US · Colorectal Cancer Metastatic, Advanced Colorectal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.